Year 2015

• Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells

  Publication

  • A. Skwarska
  • E. Augustin
  • M. Beffinger
  • A. Wojtczyk
  • S. Konicz
  • K. Laskowska
  • J. Polewska

  - BIOCHEMICAL PHARMACOLOGY - Year 2015

  Drugs targeting receptor tyrosine kinase FLT3 are of particular interest since activating FLT3-internal tandem duplication (ITD) mutations abundantly occur in fatal acute myeloid leukemias (AMLs). Imidazoacridinone C-1311, a DNA-reactive inhibitor of topoisomerase II, has been previously shown to be a potent and selective inhibitor of recombinant FLT3. Here, we expand those findings by studying its effect on leukemia cells with...

  Full text to download in external service

Year 2012

• The Role of FLT3 Kinase as an AML Therapy Target

  Publication

  • M. Beffinger
  • A. Skwarska

  - CURRENT PHARMACEUTICAL DESIGN - Year 2012

  ...

  Full text to download in external service